M1559
Moxonidine hydrochloride
≥98%
别名:
4-Chloro-6-methoxy-2-methyl-5-(2-imidazolin-2-yl)aminopyrimidine hydrochloride, BDF-5895
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C9H12ClN5O · HCl
化学文摘社编号:
分子量:
278.14
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Assay:
≥98%
Quality level:
Quality Level
assay
≥98%
originator
Solvay
SMILES string
Cl.COc1nc(C)nc(Cl)c1NC2=NCCN2
InChI
1S/C9H12ClN5O.ClH/c1-5-13-7(10)6(8(14-5)16-2)15-9-11-3-4-12-9;/h3-4H2,1-2H3,(H2,11,12,15);1H
InChI key
ZZPAWQYZQVUVHX-UHFFFAOYSA-N
Gene Information
human ... ADRA2A(150), ADRA2B(151), ADRA2C(152), NISCH(11188)
Application
Moxonidine hydrochloride has been used:
- as a standard to study its blood-brain barrier (BBB) permeability in porcine brain lipid extract by parallel artificial membrane permeability assay (PAMPA) method
- as a standard to study the chromatographic behavior and lipophilicity by reversed-phase thin-layer chromatography (RP-TLC)
- as an imidazoline I1 receptor agonist to study its effects on excitatory inputs in airway vagal preganglionic neuron (AVPN)
Biochem/physiol Actions
Moxonidine is a selective high-affinity imidazoline I1-receptor agonist and a selectively low-affinity α2-adrenoceptor agonist. It exhibits anti-hypertensive properties by reducing blood pressure efficiently. Moxonidine also exhibits spinal analgesic activity through the α2C-adrenoceptor component.
Features and Benefits
This compound is featured on the Imidazoline Binding Sites page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Solvay. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
法规信息
新产品
此项目有
Jelica Vucicevic et al.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 68, 94-105 (2014-12-30)
Imidazoline receptor ligands are a numerous family of biologically active compounds known to produce central hypotensive effect by interaction with both α2-adrenoreceptors (α2-AR) and imidazoline receptors (IRs). Recent hypotheses connect those ligands with several neurological disorders. Therefore some IRs ligands
Estimation of lipophilicity and retention behavior of some alpha adrenergic and imidazoline receptor ligands using RP-TLC
Mohamed S, et al.
Journal of Liquid Chromatography and Related Technologies, 37(20), 2829-2845 (2014)
Xujiao Zhou et al.
Brain research, 1732, 146695-146695 (2020-02-03)
As an imidazoline I1 receptor agonist with very weak binding affinity for α2-adrenoceptors, moxonidine is commonly used in the treatment of hypertension. Moxonidine also has been implicated to act centrally to reduce airway vagal outflow. However, it is unknown at
F Messerli
Journal of cardiovascular pharmacology, 35(7 Suppl 4), S53-S56 (2001-05-11)
Despite a proven efficacy in lowering blood pressure, centrally acting antihypertensive drugs are no longer widely used because of the relative high incidence of adverse effects. Most central side-effects occurring with these drugs are mediated by the alpha2-receptor. Moxonidine is
Caroline Fenton et al.
Drugs, 66(4), 477-496 (2006-04-07)
Moxonidine (Physiotens, Moxon, Cynt) is an orally administered imidazoline compound with selective agonist activity at imidazoline I1 receptors and only minor activity at alpha2-adrenoceptors. Moxonidine acts centrally to reduce peripheral sympathetic activity, thus decreasing peripheral vascular resistance. In patients with
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| M1559-25MG | 04061832091877 |
| M1559-10MG | 04061832091860 |
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持